Quantcast

Important New Research using Immunocal(R) Shows Promise in Lou Gehrig’s Disease

June 14, 2011

MONTREAL, June 14, 2011 /PRNewswire/ – Immunotec Inc. (TSXV: IMM) (www.immunotec.com/IRL/Public/en/CAN/science_research.wcp) announces that data from research using Immunocal® in a mouse model by
Principal Investigator Daniel Linseman, PhD and his team at the
University of Denver in Colorado shows promise in delaying the onset of
amyotrophic lateral sclerosis. Investigators studied mice harbouring
the gene that is responsible for some forms of the disease commonly
known as ALS or Lou Gehrig’s disease, a progressive neurodegenerative
disease that affects nerve cells in the brain and the spinal cord. The
data demonstrates for the first time that supplementation with
Immunocal may be effective in preserving blood glutathione levels which
typically diminish in affected mice. Immunocal, a whey protein isolate,
is Immunotec’s flagship product.

Dr. Linseman, is enthusiastic about the results from this study:
“Further research is essential to learn more about the strategy of
enhancing endogenous GSH levels via intake of Immunocal and its
potential benefits in ALS.” Immunotec President, Stuart Macmillan also
applauds the encouraging outcome of the study. ”Year after year,
Immunotec continues to collaborate with leading researchers and
scientists to improve the quality of life for individuals around the
world.”

Immunocal is a patented natural nutritional supplement that is
clinically proven to raise and sustain the body’s concentration of
glutathione for the maintenance of a strong immune system. “This
independent research initiative and the preliminary results are very
encouraging and we look forward to future opportunities to collaborate
in preclinical and clinical development,” says Immunotec Vice-President
of Research and Development, Mr. John Molson.

While ALS is a relatively rare disease – a total of approximately 33,000
Americans and Canadians are currently affected – it is fatal, with
eighty percent of people with ALS dying within five years of diagnosis.
Even in its early stages, the disease runs a very difficult course,
making it difficult to breathe or swallow. Especially in the United
States, costs for medical care can be significant, particularly in its
late stages.

Research team member Erika Ross presented the highlights of this study
in a poster, “A non-denatured whey protein supplement (Immunocal®)
protects neurons from mitochondrial oxidative stress and delays disease
onset in the mutant SOD1 mouse model of ALS” during the recent Keystone
Symposia on Neurodegenerative Diseases in Taos, New Mexico. The overall
findings indicate that Immunocal significantly protects cells from
oxidative stress through glutathione synthesis. The full poster can be
viewed at www.immunotec.com.

About Immunotec Inc.
Immunotec is engaged primarily in the development and marketing of
natural health products, dietary supplements, vitamins and personal
care products which are distributed throughout Canada, the United
States and Mexico through a sophisticated, seamless network marketing
channel and around the globe through exclusive distributorship
agreements.

SOURCE IMMUNOTEC INC.


Source: newswire



comments powered by Disqus